improving Oncology investigate with Integrated KRAS Assay Services and RAS Assays
during the fast evolving field of oncology analysis, precise and successful mutation screening is crucial for developing qualified therapies. The KRAS providers System plays a pivotal position in this landscape by supplying complete alternatives for KRAS mutation profiling and Evaluation. KRAS mutations, present in about 95% of RAS-linked oncogenic